OrthoPediatrics Corp. $KIDS Shares Newly Bought by Ellsworth Advisors LLC

Ellsworth Advisors LLC purchased a new position in shares of OrthoPediatrics Corp. (NASDAQ:KIDS) in the third quarter, Holdings Channel.com reports. The firm purchased 40,422 shares of the company’s stock, valued at approximately $900,000.

Several other institutional investors have also made changes to their positions in the company. AIGH Capital Management LLC bought a new stake in shares of OrthoPediatrics in the 2nd quarter valued at approximately $5,161,000. BlackRock Inc. bought a new stake in OrthoPediatrics in the second quarter worth approximately $24,347,000. Bank of New York Mellon Corp acquired a new position in shares of OrthoPediatrics during the 2nd quarter worth $992,000. Squarepoint Ops LLC increased its stake in shares of OrthoPediatrics by 95.0% during the 2nd quarter. Squarepoint Ops LLC now owns 195,468 shares of the company’s stock worth $3,739,000 after purchasing an additional 95,230 shares during the last quarter. Finally, Grandeur Peak Global Advisors LLC acquired a new position in shares of OrthoPediatrics during the 2nd quarter worth $954,000. 69.05% of the stock is currently owned by institutional investors and hedge funds.

OrthoPediatrics Stock Up 1.4%

KIDS opened at $22.57 on Friday. The business has a 50 day moving average price of $23.10 and a 200 day moving average price of $19.91. OrthoPediatrics Corp. has a twelve month low of $14.42 and a twelve month high of $26.74. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.17 and a current ratio of 4.78.

OrthoPediatrics (NASDAQ:KIDS) last announced its earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. The firm had revenue of $70.51 million during the quarter, compared to analysts’ expectations of $68.21 million. Research analysts forecast that OrthoPediatrics Corp. will post -1.14 EPS for the current year.

Analyst Ratings Changes

KIDS has been the subject of several analyst reports. Truist Financial raised shares of OrthoPediatrics to a “hold” rating in a research note on Thursday, October 1st. Needham & Company LLC upped their price objective on shares of OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Weiss Ratings raised shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 5th. BTIG Research restated a “buy” rating and set a $29.00 target price on shares of OrthoPediatrics in a report on Monday, September 14th. Finally, Piper Sandler restated an “overweight” rating and set a $25.00 target price (up from $22.00) on shares of OrthoPediatrics in a report on Wednesday, August 5th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, OrthoPediatrics presently has a consensus rating of “Moderate Buy” and an average target price of $26.50.

Insider Activity

In other news, major shareholder Jennifer Pritzker sold 326,700 shares of the business’s stock in a transaction on Friday, August 28th. The shares were sold at an average price of $23.04, for a total value of $7,527,168.00. Following the completion of the sale, the insider directly owned 6,536,764 shares in the company, valued at approximately $150,607,042.56. The trade was a 4.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David Pelizzon sold 326,700 shares of the company’s stock in a transaction on Friday, August 28th. The stock was sold at an average price of $23.04, for a total transaction of $7,527,168.00. Following the sale, the director directly owned 6,536,764 shares of the company’s stock, valued at approximately $150,607,042.56. This represents a 4.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 2,100,000 shares of company stock valued at $46,747,931 over the last 90 days. 32.50% of the stock is currently owned by company insiders.

OrthoPediatrics Profile

OrthoPediatrics Corp. is a medical device company focused exclusively on developing and commercializing orthopedic products for children. Headquartered in Warsaw, Indiana, the company designs implants and instruments intended to address the distinct anatomical and clinical needs of pediatric patients, including those whose bones are still growing.

Its product portfolio includes systems for pediatric trauma and deformity correction, scoliosis treatment, limb reconstruction, and pediatric sports medicine.